From Reddit....Recently, Ai Weixin (Suzhou) Biopharmaceutical Co., Ltd. was awarded the advanced group of national science and technology system to fight against the new crown pneumonia epidemic, and the Ministry of Science and Technology issued a certificate to Ai Weixin.
According to the "Notice of the General Office of the Ministry of Science and Technology on Recommending Advanced Groups and Individuals in the National Science and Technology System to Fight the New Coronary Pneumonia Epidemic" (National Science and Technology Office Award [2021] No. 23), the science and technology departments (commissions and bureaus) of all provinces, autonomous regions and municipalities directly under the Central Government, Xinjiang The Science and Technology Bureau of the Production and Construction Corps and the State Council's Joint Prevention and Control Mechanism for Novel Coronavirus Pneumonia Epidemic Prevention and Control Mechanism Research Team selected and recommended by each special class unit, and the National Science and Technology System's Commendation Work Leading Group for Fighting the New Coronary Pneumonia Epidemic has researched and confirmed that the national science and technology system to be commended has fought against the new coronary pneumonia. There are 163 advanced groups in the epidemic, including a number of vaccine and drug research and development teams. Aidi Weixin (Suzhou) Biopharmaceutical Co., Ltd. finally won this honor, which is the recognition of Aidi Weixin by relevant departments .
Recently, the vaccine research and development special class of the joint prevention and control mechanism of the State Council's joint prevention and control mechanism for the new coronavirus pneumonia epidemic also sent a letter of thanks to Ai Weixin, thanking Ai Weixin for his great contribution to my country's new crown vaccine research and development in the past two years. It has been highly recognized by the party and the state.
The letter of thanks points out : "In the past two years, ( Suzhou) Biopharmaceutical Co., Ltd. has a high sense of political mission and responsibility, has the courage to take responsibility, is willing to pay, overcame difficulties, united and cooperated, and in hundreds of hard days and nights, with superb Business ability Actively carry out new crown vaccine research and development, so that China's vaccine research and development has always been in the world's first phalanx, seized strategic opportunities for China's epidemic prevention and control, and made great contributions to China's vaccine research and development, which has been highly recognized by the party and the country.
Since the outbreak of the new crown epidemic, Ai Di Weixin has always taken the strategic deployment of the party and the country as the highest task, and has worked hard to make my country's deoxyribonucleic acid (DNA) vaccine technology occupy the commanding heights of the world and make my country's new crown DNA vaccine research and development always in the world's first phalanx. So far, Aidi Weixin has established a comprehensive technology platform for the design and development of DNA vaccines, large-scale production processes, high-purity plasmid production, and new delivery technologies. The independent, independent and controllable aspects of risk prevention and control and advanced technology have honorably completed the phased mission.
The new crown DNA vaccine pGX9501 developed by Ai Weixin Biopharmaceuticals is a deoxyribonucleic acid vaccine based on circular DNA plasmids. It has completed Phase I and Phase II clinical studies in China and the United States, and is conducting Phase III clinical studies in multiple countries and centers around the world. , and was selected by the World Health Organization as the global new crown vaccine solidarity test variety, and sequential immunization clinical research with inactivated vaccines is also underway. At present, Aidi Weixin has established a GMP production line for the new crown DNA vaccine, obtained a vaccine production license, and has deployed dozens of patents related to the new crown vaccine around the world, targeting the known variants of the new coronavirus and potential future variants. Broad-spectrum vaccine candidates are also in full swing.
